rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-239-254rsp-3034Research ArticleПРОБЛЕМЫ РЕВМАТОЛОГИИ В ПЕРИОД ПАНДЕМИИ КОРОНОВИРУСНОЙ БОЛЕЗНИ 2019PROBLEMS OF RHEUMATOLOGY DURING THE 2019 CORONAVIRUS PANDEMICКоронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России»Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russiahttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2

nasonov@irramn.ruhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1 

https://orcid.org/0000-0002-0797-2051МазуровВ. И.MazurovV. I.

198015, Санкт-Петербург, ул. Кирочная, 41

191015, Saint-Petersburg, Kirochnaya str., 41

https://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1391-0711КаратеевА. Е.KarateevA. E.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1771-6246ДубининаТ. В.DubininaT. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-6759-8367НикитинскаяО. А.NikitinskayaO. A.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

БарановА. А.BaranovA. A.

150000, Ярославль, ул. Революционная, 5

150000, Yaroslavl, Revolutsionnaya str., 5

https://orcid.org/0000-0001-7069-2725АбдулганиеваД. И.AbdulganievaD. I.

420012, Казань, ул. Бутлерова, 49

420012, Kazan, Butlerova str., 49

https://orcid.org/0000-0002-7232-4640МоисеевС. В.MoiseevS. V.

119991, Москва, ул. Трубецкая, 8, стр. 2

119991, Moscow, Trubetskaya str., 8, building 2

https://orcid.org/0000-0002-3235-1425ЗагребневаА. И.ZagrebnevaA. I.

117997, г. Москва, ул. Островитянова, д. 1

117997, Moscow, Ostrovityanova st., 1

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationФГБОУ ВО «СевероЗападный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University named after I.I. MechnikovRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Medical University of the Ministry of Health of RussiaRussian FederationФГБОУ ВО «Казанский государственный медицинский университет» Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationФГБОУ ВО Российский Национальный Исследовательский Медицинский Университет им. Н.И. Пирогова МЗ РФРоссияRussian National Research Medical University by N.I. PirogovaRussian Federation202113072021593239254Copyright © Насонов Е.Л., Лила А.М., Мазуров В.И., Белов Б.С., Каратеев А.Е., Дубинина Т.В., Никитинская О.А., Баранов А.А., Абдулганиева Д.И., Моисеев С.В., Загребнева А.И., 20212021Насонов Е.Л., Лила А.М., Мазуров В.И., Белов Б.С., Каратеев А.Е., Дубинина Т.В., Никитинская О.А., Баранов А.А., Абдулганиева Д.И., Моисеев С.В., Загребнева А.И.Nasonov E.L., Lila A.M., Mazurov V.I., Belov B.S., Karateev A.E., Dubinina T.V., Nikitinskaya O.A., Baranov A.A., Abdulganieva D.I., Moiseev S.V., Zagrebneva A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3034

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2), вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19), поразила более 157 млн человек во всех регионах земного шара и привела более чем к 3,2 млн летальных исходов. Предполагается, что у пациентов с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) пожилой возраст, неконтролируемое воспаление, противовоспалительная терапии, коморбидная патология, генетические и другие факторы потенциально могут приводить к увеличению восприимчивости к вирусным и бактериальным инфекциям, в том числе к SARS-CoV-2. В новой версии рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России» сформулированы основные положения, касающиеся тактики ведения пациентов с ИВРЗ в период продолжающейся пандемии COVID-19.

In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.

COVID-19иммуновоспалительные ревматические заболеваниябазисные противовоспалительные препаратыгенно-инженерные биологические препаратывакцинацияCOVID-19Immune-mediated Rheumatic DiseasesDMARDsbiologicsvaccinationReferencesWang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9World Health Organization. Coronavirus Disease (COVID-2019). Situation Reports (World Health Organization, 2020).World Health Organization. Coronavirus Disease (COVID-2019). Situation Reports (World Health Organization, 2020).Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. doi: 10.14412/1995-4484-2020-123-132Nasonov EL. Coronavirus Disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):123-132 (In Russ.). doi: 10.14412/1995-4484-2020-123-132Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.). doi: 10.47360/1995-4484-2021-5-30Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицына ТА, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-367. doi: 10.47360/1995-4484-2020-353-367Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):353-367 (In Russ.). doi: 10.47360/1995-4484-2020-353-367Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):119-128 (In Russ.). doi: 10.47360/1995-4484-2021-119-128Белов БС, Лила АМ. COVID-19 и ревматология: год спустя. Научно-практическая ревматология. 2021;59(1):31-36. doi: 10.47360/1995-4484-2021-31-36Belov BS, Lila AM. COVID-19 and rheumatology: A year later. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):31-36 (In Russ.). doi: 10.47360/1995-4484-2021-31-36Насонов ЕЛ. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019 (COVID-19): фокус на интерлейкин 6. Научно-практическая ревматология. 2020;58(3):245-261. doi: 10.14412/1995-4484-2020-245-261Nasonov EL. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): Focus on interleukin 6. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(3):245-261 (In Russ.). doi: 10.14412/1995-4484-2020-245-261Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;93(5):537-550. doi: 10.2644/00403660.2021.05.200799Nasonov EL. Coronavirus disease 2019 (COVID-19): Contribution of rheumatology. Terapevticheskiy arkhiv. 2021;93(5):537-550 (In Russ.). doi: 10.2644/00403660.2021.05.200799Merrill J, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581-589. doi: 10.1038/s41584-020-0474-5Merrill J, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581-589. doi: 10.1038/s41584-020-0474-5Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zSchett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zLiu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi: 10.1097/BOR.0000000000000776Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi: 10.1097/BOR.0000000000000776Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-XNissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-XAngriman F, Ferreyro BL, Burry L, Fan E, Ferguson ND, Husain S, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021;9(6):655-664. doi: 10.1016/S2213-2600(21)00139-9Angriman F, Ferreyro BL, Burry L, Fan E, Ferguson ND, Husain S, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021;9(6):655-664. doi: 10.1016/S2213-2600(21)00139-9Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L, et al. Immunomodulatory therapies for SARS-CoV-2 infection: A systematic literature review to inform EULAR points to consider. Ann Rheum Dis. 2021;80(6):803-815. doi: 10.1136/annrheumdis-2020-219725Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L, et al. Immunomodulatory therapies for SARS-CoV-2 infection: A systematic literature review to inform EULAR points to consider. Ann Rheum Dis. 2021;80(6):803-815. doi: 10.1136/annrheumdis-2020-219725Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315-332. doi: 10.1038/s41584-021-00608-z.Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315-332. doi: 10.1038/s41584-021-00608-z.Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol.2020; 16(8):413-414. doi: 10.1038/s41584-020-0448-7.Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol.2020; 16(8):413-414. doi: 10.1038/s41584-020-0448-7.Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19:141-154. doi: 10.1038/s41579-020-00459-7Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19:141-154. doi: 10.1038/s41579-020-00459-7Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med. 2020;217(10):e20200674. doi: 10.1084/jem.20200674Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med. 2020;217(10):e20200674. doi: 10.1084/jem.20200674Machado PM. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021;7(1):e001549. doi: 10.1136/rmdopen-2020-001549Machado PM. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021;7(1):e001549. doi: 10.1136/rmdopen-2020-001549Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. doi: 10.1056/NEJMra2026131.Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. doi: 10.1056/NEJMra2026131.Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: Dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194-6197. doi: 10.1172/JCI145301Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: Dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194-6197. doi: 10.1172/JCI145301Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428-e436. doi: 10.1016/S2665-9913(20)30120-XZhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428-e436. doi: 10.1016/S2665-9913(20)30120-XPerricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. doi: 10.1016/j.jaut.2020.102468Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. doi: 10.1016/j.jaut.2020.102468Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmunity. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmunity. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 2020;4:65. doi: 10.1186/s41927-020-00165-0Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 2020;4:65. doi: 10.1186/s41927-020-00165-0Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. medRxiv.2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. medRxiv.2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L. PostCOVID-19 arthritis: A case report and literature review. Clin Rheumatol. 2021 Feb 15:1-6. doi: 10.1007/s10067-020-05550-1Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L. PostCOVID-19 arthritis: A case report and literature review. Clin Rheumatol. 2021 Feb 15:1-6. doi: 10.1007/s10067-020-05550-1Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. doi: 10.1038/s41591-021-01283-zNalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. doi: 10.1038/s41591-021-01283-zFerri C, Giuggioli D, Raimondo V, L’Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7Ferri C, Giuggioli D, Raimondo V, L’Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol (Hoboken, NJ). 2020;72(10):1600-1606. doi: 10.1002/art.41388Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol (Hoboken, NJ). 2020;72(10):1600-1606. doi: 10.1002/art.41388Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001Aries P, Iking-Konert C. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). Ann Rheum Dis. 2020 Aug 7. doi: 10.1136/annrheumdis-2020-218400Aries P, Iking-Konert C. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). Ann Rheum Dis. 2020 Aug 7. doi: 10.1136/annrheumdis-2020-218400Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Jt Bone Spine. 2020;87(5):439-443. doi: 10.1016/j.jbspin.2020.05.003Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Jt Bone Spine. 2020;87(5):439-443. doi: 10.1016/j.jbspin.2020.05.003Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. doi: 10.1016/j.jaut.2020.102502Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. doi: 10.1016/j.jaut.2020.102502Blanch-Rubió J, Soldevila-Domenech N, Tío L, LlorenteOnaindia J, Ciria-Recasens M, Polino L, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging. 2020;12(20):19923-19937. doi: 10.18632/aging.104117Blanch-Rubió J, Soldevila-Domenech N, Tío L, LlorenteOnaindia J, Ciria-Recasens M, Polino L, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging. 2020;12(20):19923-19937. doi: 10.18632/aging.104117Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, et al. Prevalence of hospital PCR-confirmed COVID19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, et al. Prevalence of hospital PCR-confirmed COVID19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, et al. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. 2020 Jul 6. doi: 10.1136/annrheumdis-2020-218214Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, et al. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. 2020 Jul 6. doi: 10.1136/annrheumdis-2020-218214So H, Mak JW, So J, Lui G, Lun F, Lee J, et al. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Semin Arthritis Rheum. 2020;50(5):885-889. doi: 10.1016/j.semarthrit.2020.07.012So H, Mak JW, So J, Lui G, Lun F, Lee J, et al. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Semin Arthritis Rheum. 2020;50(5):885-889. doi: 10.1016/j.semarthrit.2020.07.012Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study. Ann Rheum Dis. 2020;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study. Ann Rheum Dis. 2020;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, GodoyNavarrete FJ, Cabezas-Lucena AM, Morales-Águila M, et al. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract. 2020 Sep 15. doi: 10.1111/ijcp.13707Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, GodoyNavarrete FJ, Cabezas-Lucena AM, Morales-Águila M, et al. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract. 2020 Sep 15. doi: 10.1111/ijcp.13707Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25. doi: 10.1136/annrheumdis-2020-218152Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25. doi: 10.1136/annrheumdis-2020-218152Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study. Lancet Rheumatol. 2020;2(9):e549-e556. doi: 10.1016/S2665-9913(20)30169-7Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study. Lancet Rheumatol. 2020;2(9):e549-e556. doi: 10.1016/S2665-9913(20)30169-7Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4Freites Nuñez DD, Leon L, Mucientes A, RodriguezRodriguez L, Font Urgelles J, Madrid García A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984Freites Nuñez DD, Leon L, Mucientes A, RodriguezRodriguez L, Font Urgelles J, Madrid García A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1971-1980. doi: 10.1002/art.41450Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1971-1980. doi: 10.1002/art.41450Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1981-1989. doi: 10.1002/art.41456Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1981-1989. doi: 10.1002/art.41456Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020;38(4):748-753.Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020;38(4):748-753.Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance Consortium. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 Jan 27. doi: 10.1136/annrheumdis-2020-219498Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance Consortium. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 Jan 27. doi: 10.1136/annrheumdis-2020-219498Saadoun D, Vieira M, Vautier M, Baraliakos X, Andreica I, da Silva JAP, et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: The Euro-COVIMID multicentre crosssectional study. Lancet Rheumatol. 2021 Apr 28. doi: 10.1016/S2665-9913(21)00112-0Saadoun D, Vieira M, Vautier M, Baraliakos X, Andreica I, da Silva JAP, et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: The Euro-COVIMID multicentre crosssectional study. Lancet Rheumatol. 2021 Apr 28. doi: 10.1016/S2665-9913(21)00112-0Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 May 28. doi: 10.1136/annrheumdis-2021-220418Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 May 28. doi: 10.1136/annrheumdis-2021-220418England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A National Veterans affairs matched cochort study in at-risk individuals. Arthritis Rheum. 2021 May 5. doi: 10.1002/art.41800England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A National Veterans affairs matched cochort study in at-risk individuals. Arthritis Rheum. 2021 May 5. doi: 10.1002/art.41800D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavorable outcome in hospitalized patients with rheumatic disease and COVID-19: First results of ReumaCoV Brasil Registry. RMD Open. 2021;7e0011461. doi: 10.1136/tmodopen-2020-001461Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavorable outcome in hospitalized patients with rheumatic disease and COVID-19: First results of ReumaCoV Brasil Registry. RMD Open. 2021;7e0011461. doi: 10.1136/tmodopen-2020-001461Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2020 Dec 28:keaa897. doi: 10.1093/rheumatology/keaa897Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2020 Dec 28:keaa897. doi: 10.1093/rheumatology/keaa897Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, et al. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. J Autoimmun. 2021;118:102613. doi: 10.1016/j.jaut.2021.102613Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, et al. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. J Autoimmun. 2021;118:102613. doi: 10.1016/j.jaut.2021.102613Peach E, Rutter M, Lanyon P, Grainge MJ, Hubbard R, Aston J, et al. Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic. Rheumatology. 2020;60(4):1902-1909. doi: 10.1093/rheumatology/keaa855Peach E, Rutter M, Lanyon P, Grainge MJ, Hubbard R, Aston J, et al. Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic. Rheumatology. 2020;60(4):1902-1909. doi: 10.1093/rheumatology/keaa855Hsu TY, D’Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: A retrospective, comparative cohort study. Lancet Rheumatol. 2021 May 28. doi: 10.1016/S2665-9913(21)00140-5Hsu TY, D’Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: A retrospective, comparative cohort study. Lancet Rheumatol. 2021 May 28. doi: 10.1016/S2665-9913(21)00140-5FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021 Mar 16. doi: 10.1093/rheumatology/keab250Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021 Mar 16. doi: 10.1093/rheumatology/keab250Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13. doi: 10.1136/annrheumdis-2020-218946Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13. doi: 10.1136/annrheumdis-2020-218946Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851-861. doi: 10.1007/s00296-021-04803-9Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851-861. doi: 10.1007/s00296-021-04803-9Yang H, Xu J, Shi L, Duan G, Wang Y. Correspondence on «Prevalence and clinical outocome of COVIF-19 in patients with autoimmune diseases: A systemic reviews and meta-analysis. Ann Rheum Dis. 2021;0:1-3. doi: 10.1136/annrheumdis-2020-219821Yang H, Xu J, Shi L, Duan G, Wang Y. Correspondence on «Prevalence and clinical outocome of COVIF-19 in patients with autoimmune diseases: A systemic reviews and meta-analysis. Ann Rheum Dis. 2021;0:1-3. doi: 10.1136/annrheumdis-2020-219821Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis. 2016;75(6):965-973. doi: 10.1136/annrheumdis-2016-209233Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis. 2016;75(6):965-973. doi: 10.1136/annrheumdis-2016-209233Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научнопрактическая ревматология. 2014;52(4):362-365. doi: 10.14412/1995-4484-2014-362-365Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(4):362-365 (In Russ.). doi: 10.14412/1995-4484-2014-362-365Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4Bilal J, Berlinberg A, Riaz IB, Faridi W, Bhattacharjee S, Ortega G, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1913102. doi: 10.1001/jamanetworkopen.2019.13102Bilal J, Berlinberg A, Riaz IB, Faridi W, Bhattacharjee S, Ortega G, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1913102. doi: 10.1001/jamanetworkopen.2019.13102Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020. Ann Rheum Dis. 2020;79(12):1532-1543. doi: 10.1136/annrheumdis-2020-217092Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020. Ann Rheum Dis. 2020;79(12):1532-1543. doi: 10.1136/annrheumdis-2020-217092Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61. doi: 10.1093/rheumatology/kes305Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61. doi: 10.1093/rheumatology/kes305Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the era of targeted therapies: Mapping the road ahead. Front Med (Lausanne). 2020;7:336. doi: 10.3389/fmed.2020.00336Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the era of targeted therapies: Mapping the road ahead. Front Med (Lausanne). 2020;7:336. doi: 10.3389/fmed.2020.00336Hyrich KL, Machado PM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71-72. doi: 10.1038/s41584-020-00562-2Hyrich KL, Machado PM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71-72. doi: 10.1038/s41584-020-00562-2Jethwa H, Sullivan A, Abraham S. COVID-19 and immunomodulatory therapy – Can we use data from previous viral pandemics? J Rheumatol. 2020;47(12):1734-1737. doi: 10.3899/jrheum.200527Jethwa H, Sullivan A, Abraham S. COVID-19 and immunomodulatory therapy – Can we use data from previous viral pandemics? J Rheumatol. 2020;47(12):1734-1737. doi: 10.3899/jrheum.200527Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE; CORRONA Investigators. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785-791. doi: 10.1136/ard.2010.128637Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE; CORRONA Investigators. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785-791. doi: 10.1136/ard.2010.128637Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol. 2021;35(1):101657. doi: 10.1016/j.berh.2020.101657Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol. 2021;35(1):101657. doi: 10.1016/j.berh.2020.101657Isaacs JD, Burmester GR. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019Isaacs JD, Burmester GR. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др., по поручению президиума Общероссийской общественной организации «Ассоциация ревматологов России». Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». URL: http: //rheumatology.ru (Дата доступа: ##.##.2021).Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al; on behalf of the Presidium of the All-Russian Public Organization «Association of Rheumatologists of Russia». Draft recommendations of the AllRussian public organization «Associationof Rheumatologists of Russia». Coronavirus disease 2019 (COVID-19) and immuno-inflammatory (autoimmune) rheumatic diseases (In Russ.). URL: http: //rheumatology.ru (Дата доступа: ##.##.2021).Авдеев СН, Адамян ЛВ, Алексеева УИ, Багненко СФ, Баранов АА, Баранова НН, и др. Профилактика, диагностики и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. М.;2021.Avdeev SN, Adamyan LV, Alekseeva UI, Bagnenko SF, Baranov AA, Baranova NN, et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Moscow; 2021 (In Russ.).Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi: 10.1002/art.41596Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi: 10.1002/art.41596Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C; Commission for Pharmacotherapy and the Board of Directors of the German Society for Rheumatology. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 – Methodology, key messages and justifying information. Rheumatology (Oxford). 2021 Jan 27. doi: 10.1093/rheumatology/keab072Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C; Commission for Pharmacotherapy and the Board of Directors of the German Society for Rheumatology. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 – Methodology, key messages and justifying information. Rheumatology (Oxford). 2021 Jan 27. doi: 10.1093/rheumatology/keab072Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine. 2020;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine. 2020;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, et al. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717-722. doi: 10.1111/1756-185X.13863Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, et al. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717-722. doi: 10.1111/1756-185X.13863Seo MR, Kim JW, Park EJ, Jung SM, Sung YK, Kim H, et al. Korean College of Rheumatology working group. Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic. Korean J Intern Med. 2020;35(6):1317-1332. doi: 10.3904/kjim.2020.417Seo MR, Kim JW, Park EJ, Jung SM, Sung YK, Kim H, et al. Korean College of Rheumatology working group. Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic. Korean J Intern Med. 2020;35(6):1317-1332. doi: 10.3904/kjim.2020.417Saldarriaga Rivera LM, Fernández Ávila D, Bautista Molano W, Jaramillo Arroyave D, Bautista Ramírez AJ, et al. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. Reumatol Clin (Engl Ed). 2020;16(6):437-446. doi: 10.1016/j.reuma.2020.06.011Saldarriaga Rivera LM, Fernández Ávila D, Bautista Molano W, Jaramillo Arroyave D, Bautista Ramírez AJ, et al. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. Reumatol Clin (Engl Ed). 2020;16(6):437-446. doi: 10.1016/j.reuma.2020.06.011Akintayo RO, Bahiri R, El Miedany Y, Olaosebikan H, Kalla AA, Adebajo AO, et al. African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol. 2020 Sep 2:1-10. doi: 10.1007/s10067-020-05355-2Akintayo RO, Bahiri R, El Miedany Y, Olaosebikan H, Kalla AA, Adebajo AO, et al. African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol. 2020 Sep 2:1-10. doi: 10.1007/s10067-020-05355-2Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond). 2020;20(3):256-261. doi: 10.7861/clinmed.2020-0160Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond). 2020;20(3):256-261. doi: 10.7861/clinmed.2020-0160Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, et al. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. J Eur Acad Dermatol Venereol. 2021 Feb 3. doi: 10.1111/jdv.17075Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, et al. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. J Eur Acad Dermatol Venereol. 2021 Feb 3. doi: 10.1111/jdv.17075Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf. 2021;12:2042098620985687. doi: 10.1177/2042098620985687Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf. 2021;12:2042098620985687. doi: 10.1177/2042098620985687Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734Hazlewood GS, Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, et al. Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol. 2021 May 15. doi: 10.3899/jrheum.210288Hazlewood GS, Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, et al. Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol. 2021 May 15. doi: 10.3899/jrheum.210288Santosa A, Xu C, Arkachaisri T, Kong KO, Lateef A, Lee TH, et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021 May 10. doi: 10.1111/1756-185X.14107Santosa A, Xu C, Arkachaisri T, Kong KO, Lateef A, Lee TH, et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021 May 10. doi: 10.1111/1756-185X.14107Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al. Korean College of Rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: Clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021;36(12):e95. doi: 10.3346/jkms.2021.36.e95Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al. Korean College of Rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: Clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021;36(12):e95. doi: 10.3346/jkms.2021.36.e95Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford). 2021 Mar 12. doi: 10.1093/rheumatology/keab223Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford). 2021 Mar 12. doi: 10.1093/rheumatology/keab223Soy M, Keser G, Atagunduz P, Mutlu MY, Gunduz A, Koybaşi G, Bes C. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol. 2021 Mar 22:1-13. doi: 10.1007/s10067-021-05700-zSoy M, Keser G, Atagunduz P, Mutlu MY, Gunduz A, Koybaşi G, Bes C. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol. 2021 Mar 22:1-13. doi: 10.1007/s10067-021-05700-zFurer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7(1):e001594. doi: 10.1136/rmdopen-2021-001594Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7(1):e001594. doi: 10.1136/rmdopen-2021-001594Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: An expert opinion by IMIDs Study Group. Front Immunol. 2021;12:656362. doi: 10.3389/fimmu.2021.656362Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: An expert opinion by IMIDs Study Group. Front Immunol. 2021;12:656362. doi: 10.3389/fimmu.2021.656362Hooijberg F, Boekel L, Vogelzang EH, Leeuw M, Boers M, van Vollenhoven R, et al. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2(10):e583-e585. doi: 10.1016/S2665-9913(20)30286-1Hooijberg F, Boekel L, Vogelzang EH, Leeuw M, Boers M, van Vollenhoven R, et al. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2(10):e583-e585. doi: 10.1016/S2665-9913(20)30286-1Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al.; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-XAvouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al.; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-XBower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al.; ARTIS Study Group. Impact of the COVID19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021 Feb 23. doi: 10.1136/annrheumdis-2021-219845Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al.; ARTIS Study Group. Impact of the COVID19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021 Feb 23. doi: 10.1136/annrheumdis-2021-219845Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40:2117-2118. doi: 10.1007/s00296-020-04715-0Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40:2117-2118. doi: 10.1007/s00296-020-04715-0Loarce-Martos J, García-Fernández A, López-Gutiérrez F, GarcíaGarcía V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi: 10.1007/s00296-020-04699-xLoarce-Martos J, García-Fernández A, López-Gutiérrez F, GarcíaGarcía V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi: 10.1007/s00296-020-04699-xAviv R, Weber A, Anzum T, Federbush M, Horowitz D, Singas E. Prolonged COVID-19 disease in a patient with rheumatoid arthritis on rituximab therapy. J Infect Dis. 2021 May 8. doi: 10.1093/infdis/jiab248Aviv R, Weber A, Anzum T, Federbush M, Horowitz D, Singas E. Prolonged COVID-19 disease in a patient with rheumatoid arthritis on rituximab therapy. J Infect Dis. 2021 May 8. doi: 10.1093/infdis/jiab248Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: A scoping review. Pathog Immun. 2021;6(1):76-103. doi: 10.20411/pai.v6i1.435Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: A scoping review. Pathog Immun. 2021;6(1):76-103. doi: 10.20411/pai.v6i1.435Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with noninflammatory rheumatic and musculoskeletal diseases: A US national cohort study. RMD Open. 2019;5(1):e000935. doi: 10.1136/rmdopen-2019-000935Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with noninflammatory rheumatic and musculoskeletal diseases: A US national cohort study. RMD Open. 2019;5(1):e000935. doi: 10.1136/rmdopen-2019-000935Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386(9990):258-265. doi: 10.1016/S0140-6736(14)61704-9Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386(9990):258-265. doi: 10.1016/S0140-6736(14)61704-9George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: A cohort study. Ann Intern Med. 2020;173(11):870-878. doi: 10.7326/M20-1594George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: A cohort study. Ann Intern Med. 2020;173(11):870-878. doi: 10.7326/M20-1594Каратеев АЕ, Насонов ЕЛ, Лила АМ. Вызывают ли нестероидные противовоспалительные препараты специфические осложнения при коронавирусной инфекции COVID-19? Научно-практическая ревматология. 2020;58(3):340-343. doi: 10.14412/1995-4484-2020-340-343Karateev AE, Nasonov EL, Lila AM. Do NSAIDs cause specific complications in COVID-19 coronavirus infection? Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(3):340-343 (In Russ.). doi: 10.14412/1995-4484-2020-340-343Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982. doi: 10.1016/j.biopha.2020.110982Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982. doi: 10.1016/j.biopha.2020.110982Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies. Int J Infect Dis. 2020;101:29-32. doi: 10.1016/j.ijid.2020.09.1466Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies. Int J Infect Dis. 2020;101:29-32. doi: 10.1016/j.ijid.2020.09.1466Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al.; ISARIC4C Investigators. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: A matched, prospective cohort study. Lancet Rheumatol. 2021 May 7. doi: 10.1016/S2665-9913(21)00104-1Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al.; ISARIC4C Investigators. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: A matched, prospective cohort study. Lancet Rheumatol. 2021 May 7. doi: 10.1016/S2665-9913(21)00104-1Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med. 2020;17(9):e1003308. doi: 10.1371/journal.pmed.1003308Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med. 2020;17(9):e1003308. doi: 10.1371/journal.pmed.1003308Kow CS, Hasan SS. The risk of mortality in patients with COVID19 with pre-diagnosis use of NSAIDs: A meta-analysis. Inflammopharmacology. 2021 Apr 21:1-4. doi: 10.1007/s10787-021-00810-1Kow CS, Hasan SS. The risk of mortality in patients with COVID19 with pre-diagnosis use of NSAIDs: A meta-analysis. Inflammopharmacology. 2021 Apr 21:1-4. doi: 10.1007/s10787-021-00810-1South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305-307. doi: 10.1038/s41581-020-0279-4South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305-307. doi: 10.1038/s41581-020-0279-4Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Reninangiotensin-aldosterone system blockers and the risk of COVID19. N Engl J Med. 2020;382 25):2431-2440. doi: 10.1056/NEJMoa2006923Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Reninangiotensin-aldosterone system blockers and the risk of COVID19. N Engl J Med. 2020;382 25):2431-2440. doi: 10.1056/NEJMoa2006923Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441-2448. doi: 10.1056/NEJMoa2008975Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441-2448. doi: 10.1056/NEJMoa2008975Egeli BH, Sparks JA, Kim AHJ, Liew JW. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best Pract Res Clin Rheumatol. 2021;35(1):101658. doi: 10.1016/j.berh.2020.101658Egeli BH, Sparks JA, Kim AHJ, Liew JW. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best Pract Res Clin Rheumatol. 2021;35(1):101658. doi: 10.1016/j.berh.2020.101658Ladapo JA, McKinnon JE, McCullough PA, Risch H. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. MedRxiv. 2020. doi: 10.1101/2020.09.30.20204693Ladapo JA, McKinnon JE, McCullough PA, Risch H. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. MedRxiv. 2020. doi: 10.1101/2020.09.30.20204693Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117-134. doi: 10.1080/07853890.2020.1839959Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117-134. doi: 10.1080/07853890.2020.1839959Ferreira A, Oliveira ESA, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2. J Med Virol. 2020;93(2):755-759. doi: 10.1002/jmv.26286Ferreira A, Oliveira ESA, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2. J Med Virol. 2020;93(2):755-759. doi: 10.1002/jmv.26286Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ 2nd. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: A retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689-e697. doi: 10.1016/S2665-9913(20)30305-2Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ 2nd. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: A retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689-e697. doi: 10.1016/S2665-9913(20)30305-2Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: A population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-e27. doi: 10.1016/S2665-9913(20)30378-7Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: A population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-e27. doi: 10.1016/S2665-9913(20)30378-7Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166. doi: 10.1038/s41584-020-0372-xSchrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166. doi: 10.1038/s41584-020-0372-xAringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020;22(1):290. doi: 10.1186/s13075-020-02395-6Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020;22(1):290. doi: 10.1186/s13075-020-02395-6Schäfer M, Strangfeld A, Hyrich KL, Carmona L, Gianfrancesco M, Lawson-Tovey S, et al. Response to: “Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID19 Global Rheumatology Alliance physician reported registry’” by Mulhearn et al. Ann Rheum Dis. 2021 Mar 1. doi: 10.1136/annrheumdis-2021-220134Schäfer M, Strangfeld A, Hyrich KL, Carmona L, Gianfrancesco M, Lawson-Tovey S, et al. Response to: “Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID19 Global Rheumatology Alliance physician reported registry’” by Mulhearn et al. Ann Rheum Dis. 2021 Mar 1. doi: 10.1136/annrheumdis-2021-220134Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Pivonello R, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43(8):1141-1147. doi: 10.1007/s40618-020-01266-wIsidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Pivonello R, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43(8):1141-1147. doi: 10.1007/s40618-020-01266-wRECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and nonCOVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-537. doi: 10.1007/s00134-021-06394-2Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and nonCOVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-537. doi: 10.1007/s00134-021-06394-2The REMAP-CAP Investigators, Gordon CA, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – Preliminary report. medRxiv 2021. doi: 10.1101/2021.01.07.21249390The REMAP-CAP Investigators, Gordon CA, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – Preliminary report. medRxiv 2021. doi: 10.1101/2021.01.07.21249390RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021. doi: 10.1101/2021.02.11.21249258RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021. doi: 10.1101/2021.02.11.21249258Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: A meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021 May 21:1-12. doi: 10.1007/s00134-021-06416-zSnow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: A meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021 May 21:1-12. doi: 10.1007/s00134-021-06416-zTardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. 2021. doi: 10.1101/2021.01.26.21250494Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. 2021. doi: 10.1101/2021.01.26.21250494Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. doi: 10.14412/1995-4484-2020-183-190Alekberova ZS, Nasonov EL. Prospects for using colchicine in medicine: new evidence. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):183-190 (In Russ.). doi: 10.14412/1995-4484-2020-183-190Chiu L, Chow R, Chiu N, Lo C-H, Aggarwal R, Lee J, et al. Colchicine use in patients with COVID-19: A systematic review and meta-analysis. medRxiv. 2021. doi: 10.1101/2021.02.02.21250960Chiu L, Chow R, Chiu N, Lo C-H, Aggarwal R, Lee J, et al. Colchicine use in patients with COVID-19: A systematic review and meta-analysis. medRxiv. 2021. doi: 10.1101/2021.02.02.21250960Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научнопрактическая ревматология. 2020;58(3):304-316. doi: 10.14412/1995-4484-2020-304-316Nasonov EL, Lila AM. Baricitinib: New pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(3):304-316 (In Russ.). doi: 10.14412/1995-4484-2020-304-316Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020 Dec 11. doi: 10.1056/NEJMoa2031994Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020 Dec 11. doi: 10.1056/NEJMoa2031994Mehta P, Ciurtin C, Scully M, Levi M, Chambers RC. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56(3):2001919. doi: 10.1183/13993003.01919-2020Mehta P, Ciurtin C, Scully M, Levi M, Chambers RC. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56(3):2001919. doi: 10.1183/13993003.01919-2020Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2019:464.Nasonov EL (ed.). Rheumatology. Russian clinical guidelines. Moscow:GEOTAR-Media;2019:464 (In Russ.).Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616. doi: 10.1016/S0140-6736(20)32318-7Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616. doi: 10.1016/S0140-6736(20)32318-7Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765. doi: 10.1016/j.autrev.2012.02.001Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765. doi: 10.1016/j.autrev.2012.02.001Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol. 2021;93(4):2385-2395. doi: 10.1002/jmv.26740Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol. 2021;93(4):2385-2395. doi: 10.1002/jmv.26740Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694-700. doi: 10.1016/j.ajic.2021.02.012Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694-700. doi: 10.1016/j.ajic.2021.02.012Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021;3(4):e241-e243. doi: 10.1016/S2665-9913(21)00037-0Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021;3(4):e241-e243. doi: 10.1016/S2665-9913(21)00037-0Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021;49(2):137-142. doi: 10.1016/j.ajic.2020.11.018Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021;49(2):137-142. doi: 10.1016/j.ajic.2020.11.018Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8Schulze-Koops H, Specker C, Skapenko A. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: Considerations before widespread availability of the vaccines. RMD Open. 2021;7(1):e001553. doi: 10.1136/rmdopen-2020-001553Schulze-Koops H, Specker C, Skapenko A. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: Considerations before widespread availability of the vaccines. RMD Open. 2021;7(1):e001553. doi: 10.1136/rmdopen-2020-001553Calabrese L, Winthrop KL. Rheumatology and COVID-19 at 1 year: Facing the unknowns. Ann Rheum Dis. 2021 March 3. doi: 10.1136/annrheumdis-2021-219957Calabrese L, Winthrop KL. Rheumatology and COVID-19 at 1 year: Facing the unknowns. Ann Rheum Dis. 2021 March 3. doi: 10.1136/annrheumdis-2021-219957Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220408.Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220408.Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021 Apr 9. doi: 10.1101/2021.04.05.21254656Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021 Apr 9. doi: 10.1101/2021.04.05.21254656Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23. doi: 10.1136/annrheumdis-2021-220289Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23. doi: 10.1136/annrheumdis-2021-220289Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021 May 11. doi: 10.1136/annrheumdis-2021-220604Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021 May 11. doi: 10.1136/annrheumdis-2021-220604Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 Mar 24. doi: 10.1136/annrheumdis-2021-220272Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 Mar 24. doi: 10.1136/annrheumdis-2021-220272Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220461Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220461Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 25 May 2021. doi: 10.1136/annrheumdis-2021-220597Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 25 May 2021. doi: 10.1136/annrheumdis-2021-220597Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov19 vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov19 vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Med. 2021;18(5):e1003648. doi: 10.1371/journal.pmed.1003648.Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Med. 2021;18(5):e1003648. doi: 10.1371/journal.pmed.1003648.Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021;121:102663. doi: 10.1016/j.jaut.2021.102663Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021;121:102663. doi: 10.1016/j.jaut.2021.102663Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1Белов БС. Вакцинация при ревматических заболеваниях: союзник или противник? Научно-практическая ревматология. 2018;56(4):401-404.Belov BS. Vaccination in rheumatic diseases: An ally or an enemy? Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(4):401-404 (In Russ.).Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135-145. doi: 10.1038/nrrheum.2014.206Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135-145. doi: 10.1038/nrrheum.2014.206Furer V, Rondaan C, Heijstek MW, van Assen S, Bijl M, Breedveld FC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882Furer V, Rondaan C, Heijstek MW, van Assen S, Bijl M, Breedveld FC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019;5(2):e001035. doi: 10.1136/rmdopen-2019-001035Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019;5(2):e001035. doi: 10.1136/rmdopen-2019-001035

The authors declare that there are no conflicts of interest present.